Key Highlights

  • Third-quarter 2026 Revenue was USD 7.6 million, against USD 7.9 million in the second quarter.
  • Hospital revenue was USD 6.8 million, against USD 6.7 million in the prior quarter.
  • GAAP net loss was USD 11.4 million, or USD 0.64 per share.
  • The company raised the low end of its 2026 revenue range to USD 28 million.

BioStem Technologies (NASDAQ:BSEM) reported revenue of USD 7.6 million for the third quarter ended September 30, 2026, against an estimate of USD 7.17 million and USD 7.9 million in the second quarter of 2026. GAAP net loss was USD 0.64 per share, against an estimate of a loss of USD 0.43. The company, which commenced trading on the Nasdaq Capital Market in August, described the quarter as its second full quarter operating as a predominantly hospital-focused business.

Quarterly Financial Results

Chief Financial Officer Brandon Poe said hospital revenue rose to USD 6.8 million from USD 6.7 million in the prior quarter, while physician office revenue was USD 810,000, against USD 1.1 million. Gross Profit was USD 4.3 million, a gross Margin of 56%, against USD 4.8 million and 61% in the second quarter. He attributed the sequential decline primarily to higher Transfer Pricing under the BioTissue Supply agreement following the expiration of the initial discounted pricing.

Total operating expenses were USD 14.1 million, against USD 13.2 million in the prior quarter. Sales and Marketing expenses were USD 5.3 million, general and administrative expenses were USD 7.5 million, against USD 6.5 million, and Research and Development expenses were approximately USD 0.5 million, against approximately USD 0.7 million.

GAAP net loss was USD 11.4 million, or USD 0.64 per share, against USD 9 million, or USD 0.52 per share, in the second quarter. The net loss included a USD 1 million payment to BioTissue to extend the clearance payment deadline. Adjusted EBITDA loss was USD 6.4 million, against USD 4.6 million.

Cash, Financing and Going-Concern Disclosure

Cash and cash equivalents were USD 1 million as of September 30, 2026, against USD 7 million as of June 30, 2026. Cash used in Operating Activities was USD 8.8 million, against USD 5.5 million in the second quarter. In September, the company put in place a USD 40 million committed Equity Facility with ROTH Capital Partners and had not sold any shares under it to date. It closed a private Placement generating gross proceeds of approximately USD 3 million, with potential for up to approximately USD 5.6 million more if the accompanying warrants are exercised in full for cash.

In October, the company received USD 1 million from option exercises by its Chief Executive Officer and Chief Operating Officer. The Quarterly Report states that substantial doubt exists about the company's ability to continue as a Going Concern for at least one year from the issuance of the financial statements.

Cost Reduction Plan and Outlook

Management said it is evaluating a cost reduction plan that would lower annualized cash operating expenses by approximately USD 10 million to USD 12 million. It also plans to move Neox and Clarix production into its Pompano Beach facility, with the technology transfer targeted for the first half of 2027. Management said gross margins are projected to remain in the 50s until then.

The company now projects full-year 2026 revenue of USD 28 million to USD 29 million, against its previous range of USD 26 million to USD 29 million. It projects sequential hospital revenue growth in the fourth quarter and minimal contribution from the physician office channel. The company said the transition services agreement with BioTissue concluded at the start of August, with sales logistics, invoicing, collections and inventory management now handled in-house.